Sandra Porcile Rojas-Caro
Director/Board Member presso RIPLEY CORP S.A.
Posizioni attive di Sandra Porcile Rojas-Caro
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| RIPLEY CORP S.A. | Director/Board Member | 01/01/2020 | - |
| Independent Dir/Board Member | 01/01/2020 | - |
Storia della carriera di Sandra Porcile Rojas-Caro
Precedenti posizioni note di Sandra Porcile Rojas-Caro
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 24/05/2021 | 28/10/2022 |
| GEMI THER | Chief Tech/Sci/R&D Officer | - | - |
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 16/05/2016 | - |
| SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | 01/01/2013 | - |
Formazione di Sandra Porcile Rojas-Caro
| Pontificia Universidad Católica de Chile | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Cile | 3 |
Posizioni
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 5 |
| Retail Trade | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| RIPLEY CORP S.A. | Retail Trade |
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
